Conclusion
In conclusion, the 12 SQ tree SLIT-tablet was well tolerated in tree pollen allergic subjects with no major safety concerns detected. The majority of the most frequently reported IMP-related AEs were local allergic reactions primarily in the oral cavity and throat. They resolved without treatment, and they were mild or moderate in severity with the onset of the most frequently reported local reactions on day 1.
This safety profile supports daily at-home sublingual administration once the first dose is tolerated when administered under medical supervision. Additional studies should investigate the long-term safety and tolerability of the SQ tree SLIT-tablet.